Objective Helicobacter pylori is classified by the World Health Organisation as a carcinogen leading to gastritis and gastric cancer, the second most lethal cancer. The biggest challenge is to identify the infection at an early stage and give a more complete intervention as more than 85% of infections are asymptomatic. This makes screening/ testing an important primary action in combating H. pyrlori and its life threatening effects. Current non-invasive diagnosis methods are based on radiolabelling and are costly, cumbersome to the technician, inappropriate for wide spread clinical use and time consuming in delivering test results.AM-SENSE is a completely new and low-cost hand held electrochemical breathalyser device to efficiently and accurately measure the presence of ammonia in a person's breath to screen for H. pyroli giving ‘instant results’. Costs per test will decrease from an average of €60 to €9.50. The key markets for our product are Europe, Asia and the USA. We project, through manufacturing, retailing and licensing of AM-SENSE a turnover of €59 million in 5 years creating 35 new jobs. A sales forecast of 125,000 units has been set for the 5 year post commercialisation period. This will result in reduced gastric cancer incidence, cheaper and faster treatment for H. pyroli infection and lower all round societal cost.In Phase 1 we intend to test AM-SENSE against gold standards and conduct a more intensified market study, tapping into the knowledge of breathalyser companies through partnerships.In Phase 2 we intend to integrate the electrodes and electronics with the breath capture device into a single market ready prototype and validate with potential clients. Fields of science natural scienceschemical scienceselectrochemistryengineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsmedical and health sciencesclinical medicineoncologysocial sciencessociologygovernancecrisis management Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-1-2015 Funding Scheme SME-1 - SME instrument phase 1 Coordinator KANICHI RESEARCH SERVICES LIMITED Net EU contribution € 50 000,00 Address HOPE ROAD 41 SALE M33 3BF MANCHESTER United Kingdom See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region North West (England) Greater Manchester Greater Manchester South West Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
